Close



Jan 31, 2023 06:45AM
Oct 4, 2022 07:35AM
Oct 4, 2022 07:30AM
Oct 3, 2022 01:01PM
Oct 3, 2022 01:01PM
Aug 5, 2022 07:00AM
Jun 13, 2022 07:30AM Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Z
Jun 9, 2022 07:30AM
May 23, 2022 07:31AM
May 23, 2022 07:30AM
May 28, 2021 09:25AM
May 27, 2021 05:45PM
Mar 1, 2021 07:30AM
Dec 16, 2020 07:31AM Biohaven Pharma's (BHVN) Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
Dec 16, 2020 07:30AM
Dec 1, 2020 03:05AM
Nov 16, 2020 07:34AM
Nov 16, 2020 07:30AM
Nov 9, 2020 08:00AM
Oct 14, 2020 07:32AM
Oct 14, 2020 07:30AM U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine
Feb 25, 2020 04:45PM
Feb 10, 2020 07:37AM
Feb 10, 2020 07:25AM
Jan 29, 2020 10:27AM
Dec 17, 2019 07:31AM
Dec 17, 2019 07:30AM
Nov 1, 2019 04:15PM Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
Jun 26, 2019 06:40AM
May 8, 2019 07:24AM
May 7, 2019 06:55AM
Feb 28, 2019 04:30PM

12,332 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All